The National Pharmaceutical Pricing Authority (NPPA) on Monday announced it has revised prices of bulk drugs and formulation to make them cheaper and affordable to the affected people.
"Ceiling prices of 31 scheduled formulation packs of intravenous fluids and 25 other formulations have been revised on June 3 and June 2 along with eight formulations under the Drugs (price control) amendment order," the authority said here in a notification here.
Set up by the Union Ministry of Chemicals and Fertilizers, the authority fixes, revises and enforces prices of various controlled drugs. It also levies and collects penalties from manufacturers if customers are overcharged.
It also monitors prices of decontrolled drugs to keep them affordable to the needy.
The fresh order supersedes that of March 2, 2016, February 26, 2015 and December 10, 2014 on formulation packs.
The ceiling prices are exclusive of local taxes where ever applicable.
Among the medicines whose prices have been revised include glucose and sodium chloride injections and their combined injections.
The pharma firms whose drug prices have been revised lower are Abbot Healthcare, Adcock Ingram Healthcare, Alembic, Bennet Pharmaceuticals, Cadila Pharma, Cipla and others.
--IANS
fb/vd
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
